Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Iovance Biotherapeutics progresses on BLA for lifileucel, faces recruitment challenges

Iovance Biotherapeutics is on track with BLA completion expected this quarter, strong pipeline progress, and manufacturing capacity expansion. Challenges include study recruitment uncertainties and the ongoing CEO search. Opportunities exist in new program data releases, European expansion, and pivotal study enrollment.

Iovance Biotherapeutics advances TIL therapy pipeline with strong financials

Iovance Biotherapeutics is on track with key milestones in TIL therapy development and commercialization.
The company's financial position is stable, with strategic investments supporting future growth.
Challenges include operational efficiency, FDA interactions, and trial progress management.
Opportunities lie in international trials, market expansion, and revenue growth post-launch.

Iovance Biotherapeutics reports Q2 loss, eyes lifileucel FDA review

Iovance Biotherapeutics faces financial challenges with a significant net loss in Q2 2023, despite positive milestones and revenue from Proleukin sales.
The company's TIL therapy pipeline shows promise with progress in key clinical trials, while opportunities exist for market differentiation and revenue growth.
Challenges include ongoing financial losses, longer timelines for pivotal studies, and potential delays in trial enrollment, requiring strategic management.

Iovance Biotherapeutics progresses on Lifileucel commercialization and pipeline expansion

Iovance Biotherapeutics is making significant strides in advancing its pipeline and commercialization efforts, with a strong focus on FDA approval for Lifileucel and expanding into key markets. The company faces challenges in labeling discussions and efficacy benchmarks but has opportunities in European marketing, new therapy programs, and potential partnerships for international growth.

Iovance Biotherapeutics excels with Amtagvi approval and clinical progress

Iovance Biotherapeutics showcased strong performance with the FDA approval of Amtagvi and progress in clinical trials, positioning the company for growth.
While facing challenges in scaling operations and regulatory hurdles, the company's focus on efficiency and clinical research strengths bode well for the future.
With opportunities in label expansion, market penetration, and revenue growth, Iovance is poised to capitalize on its innovative therapies and drive value for stakeholders.

Iovance Biotherapeutics reports Q1 loss, Amtagvi launch success

Iovance Biotherapeutics shows promising performance with a focus on Amtagvi's commercial success and pipeline advancements.
Strengths include positive reimbursement trends, successful patient selection processes, and efficient manufacturing operations.
Challenges lie in patient screening failures, financial clearance issues, and variability in bridging therapy usage.
Opportunities for growth include market expansion, high patient conversion rates, and accelerated submission processes for new therapies.

Iovance Biotherapeutics (IOVA) exceeds Q3 revenue targets, eyes global expansion

Iovance Biotherapeutics (IOVA) had a strong Q3 performance, exceeding revenue guidance and showcasing growth potential.
The company's focus on Amtagvi and global expansion presents opportunities for revenue diversification and market penetration.
Challenges lie in maintaining adoption rates, meeting revenue targets, and effectively managing increased manufacturing capacity.
Overall, IOVA's strategic initiatives position it for continued growth and success in the biopharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Iovance Biotherapeutics is now selling its first cell therapy, Amtagvi. Amtagvi requires significant logistical and manufacturing coordination.

This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock

Iovance's Q2 2024 revenue of $31.1 million surpassed analyst expectations. Amtagvi, Iovance's TIL therapy, generated $12.8 million in its first full quarter post-approval. Iovance's ongoing trials in NSCLC and endometrial cancer could expand lifileucel's market potential.

Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)

Although only approved in February, Iovance's Amtagvi is already selling well. The drug in question also has potential as a treatment for several other types of cancer.

Why Iovance Biotherapeutics Shares Are Soaring Today

Iovance Biotherapeutics (NASDAQ: IOVA ) stock is taking a beating on Friday after the biotechnology company announced its earnings for the second quarter of the year. Iovance Biotherapeutics starts that report with adjusted earnings per share of -34 cents.

Why Is Iovance Bio (IOVA) Stock Up 18% Today?

Iovance Biotherapeutics Inc IOVA stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings.

Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges

Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Sara Pellegrino – Senior Vice President, Investor Relations and Corporate Communications Fred Vogt – Interim President and Chief Executive Officer Jim Ziegler – Executive Vice President-Commercial Igor Bilinsky – Chief Operating Officer Jean-Marc Bellemin – Chief Financial Officer Friedrich Finckenstein – Chief Medical Officer Brian Gastman – Executive Vice President-Medical Affairs Conference Call Participants Michael Yee – Jefferies Peter Lawson – Barclays Andrea Tan – Goldman Sachs Yanan Zhu – Wells Fargo Securities Tyler Van Buren – TD Cowen Ben Burnett – Stifel Colleen Kusy – Baird Asthika Goonewardene – Truist Reni Benjamin – Citizens JMP Operator Welcome to the Iovance Biotherapeutics Conference Call to discuss Second Quarter 2024 Results and Recent Corporate Updates. My name is Daniel and I will be your operator for today's call.

Iovance Biotherapeutics, Inc. (IOVA) Q2 2024 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.47 per share a year ago.

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25 SAN CARLOS, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter and first half 2024 financial results and corporate updates.

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024

Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Archer Aviation

Alarm.com

AeroVironment

CRISPR Therapeutics

DraftKings

Harmonic

Iridium Communications

Kratos Defense & Security Solutions

Rocket Lab USA

Big tech stocks cooled off in July, while smaller growth companies rallied. An anticipated rate cut could amplify this trend reversal in August and beyond.

10 Best Small and Mid-Cap Stocks to Consider Buying in August

An analyst from Piper Sandler recently downgraded Iovance Biotherapeutics and lowered the firm's price target on the stock The FDA approved Iovance's first drug in February, and investors still aren't sure if its commercial launch can succeed. An ongoing clinical trial could greatly expand the addressable patient population for the company's lead drug.

Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?

An analyst downgraded his recommendation on the biotech. In spite of that, these are exciting times for Iovance.

Why Iovance Biotherapeutics Stock Stumbled Today

SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.

Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024

Piper Sandler downgraded Iovance Biotherapeutics Inc IOVA, citing the slow launch of Amtagvi (lifileucel), a prescription medicine used to treat adults with a type of skin cancer that cannot be removed surgically or has spread to other parts of the body called unresectable or metastatic melanoma.

Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy

Viking Therapeutics

The cost of taking out fresh debt is an important consideration for some biotechs. There's reason to believe that debt financing is about to get a bit cheaper.

Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why.

CoreCivic

Hormel Foods

Kura Sushi USA

Medtronic

Block

TAL Education Group

Death cross stocks – on the surface, the title sounds incredibly menacing. However, it may be one of the more misunderstood concepts.

7 ‘Death Cross' Stocks That Could Be Contrarian Buys

Iovance Biotherapeutics just launched its first therapy. Its revenue is likely to start ramping up.

Is Iovance Biotherapeutics a Millionaire Maker?

Actinium Pharmaceuticals

Geron

Low-cap biotech companies are a high-risk but high-reward investment choice. If their clinical trials are successful, that can often mean an explosion in value as investors anticipate a buyout.

3 Under-$10 Biotech Stocks That Could Make You Rich

First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for lifileucel, a TIL cell therapy, for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma

Iovance's shares took off earlier this year after its cell therapy obtained accelerated approval. The company, however, still remains deeply unprofitable and is burning through cash at a high rate.

Is It Too Late to Buy Iovance Biotherapeutics Stock?

3D Systems

Uranium Energy

Many people overlook penny stocks due to the inherent risk of investing in them. The stocks are infamous for producing poor results and being too hard to trade profitably.

3 Top Penny Stocks to Skyrocket Your Wealth in 2024

Iovance Biotherapeutics makes a cell therapy called Amtagvi for melanoma. Amtagvi isn't currently approved as a first-line treatment.

The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why

SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events:

Iovance Biotherapeutics to Present at Upcoming Conferences and Events

Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.

News for Iovance Biotherapeutics Stock (IOVA)